Physiomics PLC Presentation and Q&A on Company's Final Results
October 06 2020 - 4:00AM
RNS Non-Regulatory
TIDMPYC
Physiomics PLC
06 October 2020
6 October 2020
Physiomics plc
("Physiomics" or "the Company")
Presentation and Q&A on Company's Final Results for the year
ended 30 June 2020
Physiomics plc (AIM: PYC), the oncology consultancy using
mathematical models to support the development of cancer treatment
regimens and personalised medicine solutions, yesterday made a
presentation regarding its final results for the year ended 30 June
2020, using the Investor Meet Company platform. The slide deck used
in the presentation can be accessed on our website
https://www.physiomics.co.uk/wp-content/uploads/2020/10/Physiomics-Update-30-Sept-2020-vfinalr.pdf
and a recording of the presentation, together with the subsequent
Q&A, can be viewed by registering or logging on to Investor
Meet Company at:
https://www.investormeetcompany.com/physiomics-plc/register-investor
.
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
Richard Tulloch & James Dance
+44 (0)20 7409 3494
About Physiomics
Physiomics plc (AIM: PYC) is an oncology consultancy using
mathematical models to support the development of cancer treatment
regimens and personalised medicine solutions. The Company's Virtual
Tumour(TM) technology uses computer modelling to predict the
effects of cancer drugs and treatments to improve the success rate
of drug discovery and development projects while reducing time and
cost. The predictive capability of Physiomics' technologies have
been confirmed by over 70 projects, involving over 30 targets and
60 drugs, and has worked with clients such as Merck KGaA, Merck
& Co, Bayer and Lilly.
Based in Oxford UK, the Company works with clients worldwide to
support their pre-clinical and clinical oncology development
programs. Its team of scientists and computer modelling experts
provide bespoke solutions encompassing data, analytics and
insight.
Physiomics senior management has academic and commercial
expertise, including over 120 years collectively of working in
oncology and/or computational biology and over 120 publications in
peer reviewed journals that have attracted thousands of
citations.
For more information please visit:
www.physiomics.co.uk
www.twitter.com/Physiomics
www.linkedin.com/company/physiomics-plc/
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAUNVBRRVURRRA
(END) Dow Jones Newswires
October 06, 2020 04:00 ET (08:00 GMT)
Physiomics (LSE:PYC)
Historical Stock Chart
From Apr 2024 to May 2024
Physiomics (LSE:PYC)
Historical Stock Chart
From May 2023 to May 2024